Biotech Company Named In Securities Suit Over COVID-19 Blood Test Misstatements

(January 19, 2021, 1:52 PM EST) -- LOS ANGELES — A biotechnology company and its CEO violated federal securities law by misrepresenting to investors that the company had developed a rapid-result finger-prick blood test for the detection of...
To view the full article, register now.